<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759352</url>
  </required_header>
  <id_info>
    <org_study_id>GEO-STAR</org_study_id>
    <nct_id>NCT04759352</nct_id>
  </id_info>
  <brief_title>Telephone Versus In-person Post-test Cancer Genetic Counseling</brief_title>
  <acronym>GEO-STAR</acronym>
  <official_title>Cancer Genetic Counseling: Telephone Versus Standard In-person Delivery. A Randomized Trial (GEO-STAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the GEO-STAR randomized non-inferiority trial is to compare the outcome of&#xD;
      post-test telephone cancer genetic counseling with standard in-person cancer genetic&#xD;
      counseling. We hypothesize that telephone counseling is non-inferior by outcome if compared&#xD;
      to standard in-person counseling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients undergoing pre-test cancer genetic counseling and cancer genetic&#xD;
      testing, during the study period, will be eligible to participate. During the pre-test&#xD;
      genetic counseling, demographic data, family and personal medical history will be collected&#xD;
      and pedigree will be drawn. Available participants will provide written informed consent.&#xD;
      They will be then randomized in blocks of ten participants using an online system&#xD;
      (http://wwwservizi.regione.emilia-romagna.it/generatore/).&#xD;
&#xD;
      The study is open label; thus, patients and investigators will not be blinded to treatment&#xD;
      allocation due to the study nature intervention.&#xD;
&#xD;
      After randomization, participants will be scheduled for post-test genetic counseling session.&#xD;
      Participants randomized to usual care will receive standard in-person result disclosure.&#xD;
      Participants randomized to telephone counseling will be scheduled for telephone post-test&#xD;
      counseling sessions. One-week after completing the post-test genetic counseling session, the&#xD;
      survey package will be sent by email to participants to assess impact and satisfaction with&#xD;
      post-test counseling.&#xD;
&#xD;
      Genetic counselors delivering post-test genetic counseling will complete the questionnaire&#xD;
      immediately after the post-test session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Multidimensional Impact of Cancer Risk Assessment&quot; questionnaire</measure>
    <time_frame>Seven days after the post-test genetic counseling session</time_frame>
    <description>Impact of post-test counseling on patients. The &quot;Multidimensional Impact of Cancer Risk Assessment&quot; questionnaire measures distress, uncertainty and positive experiences associated to cancer genetic testing. A version adapted to the Italian context will be used, where a single item related to insurance has been removed because not applicable to the Italian Health System. The resulting possible scores range from 0 to 100. Higher scores indicate more negative impacts of cancer risk assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Patient perceptions of the genetic counseling questionnaire&quot;</measure>
    <time_frame>Seven days after the post-test genetic counseling session</time_frame>
    <description>Impact of post-test counseling on patients. The range of scores is from 8 to 31. Higher scores indicate positive perception of the genetic counseling session.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;Genetic Counselor process Questionnaire&quot;</measure>
    <time_frame>Immediately after the post-test genetic counseling session</time_frame>
    <description>Professionals perceptions measured by the Genetic Counselor process Questionnaire completed by professionals who provided the post-test genetic counseling. The range of scores is from 4 to 20. Higher scores indicate positive perception of the genetic counselor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of sociodemographic and medical history on genetic counseling outcomes</measure>
    <time_frame>Data collection during pre-test genetic counseling session</time_frame>
    <description>Sociodemographic variables and family and personal cancer history will be collected during the pre-test session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of logistics on genetic counseling preferences</measure>
    <time_frame>Data collection during the pre-test genetic counseling session</time_frame>
    <description>Distance (in kilometers) of patient's primary residence to the clinic location collected by the demographic data collected at pre-test genetic counseling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">724</enrollment>
  <condition>Cancer Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Telephone post-test genetic counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-test genetic counseling delivered by telephone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-person post-test genetic counseling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Post-test genetic counseling delivered in-person</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Post-test genetic counseling delivered by telephone</intervention_name>
    <description>Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.</description>
    <arm_group_label>Telephone post-test genetic counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age inclusive at the time of the study;&#xD;
&#xD;
          -  Patients must have undergone an in-person pre-test genetic counseling session;&#xD;
&#xD;
          -  Patients must have undertaken cancer genetic testing;&#xD;
&#xD;
          -  Patients must be able to speak Italian fluently;&#xD;
&#xD;
          -  Patients must have got an email address.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to provide informed consent, for example due to mental incapacity or&#xD;
             active psychotic illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lea Godino</last_name>
    <phone>0512143694</phone>
    <phone_ext>+39</phone_ext>
    <email>lea.godino@aosp.bo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>UO Genetica Medica, IRCCS AOU di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Godino, PhD</last_name>
      <phone>0512143694</phone>
      <email>lea.godino@aosp.bo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Daniela Turchetti</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>genetic telecounselling</keyword>
  <keyword>test result communication</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

